Cardiff Oncology, Inc. (CRDF)

Cardiff Oncology's stock price has been influenced by earnings reports, clinical trial data and updates, capital raise, patent issuance, analyst ratings and price targets, and stock performance. The company announced financial results for Q4 2024, Q1 2025, and Q2 2025, reporting net losses. Positive initial data from the CRDF-004 trial was shared, but a delay in trial data readout caused a stock decline. The company completed an oversubscribed $40 million underwritten registered direct offering. New patents were issued for the use of onvansertib in combination with bevacizumab. Analysts have generally been bullish, with a consensus rating of "Moderate Buy". The stock experienced volatility, with a significant rise followed by a decline, and as of October 24, 2025, was trading around $2.23.

As a clinical-stage biotechnology company without commercialized products, traditional product demand seasonality is not applicable to Cardiff Oncology's current business model. Investor interest, influenced by clinical trial progress, regulatory milestones, financial updates, and market sentiment, primarily drives the "demand" for Cardiff Oncology.

Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing innovative cancer therapies, particularly for unmet medical needs. The company operates in the healthcare sector, specifically in the biotechnology industry, focusing on medical specialties and biomedical and genetics. Their primary product candidate is onvansertib, a first-in-class PLK1 inhibitor, being evaluated in combination with standard-of-care therapies across various clinical programs, including studies for RAS-mutated metastatic colorectal cancer, metastatic castrate-resistant prostate cancer, relapsed or refractory acute myeloid leukemia, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple-negative breast cancer.

Cardiff Oncology, Inc. is headquartered in San Diego, California, United States. The company plans to establish a global presence by seeking regulatory approvals in key markets such as the United States, Europe, and Asia, and is exploring opportunities for international partnerships.

Cardiff Oncology's brand reputation appears generally positive, driven by clinical progress. Investor sentiment is considered "very positive," and the company has a consensus rating of "Moderate Buy" from analysts. News sentiment is generally positive. Positive clinical trial data and patent issuance have positively impacted the company's reputation, while a trial data delay may have temporarily impacted investor confidence. The company continues to operate at a net loss, which can be a point of caution for some investors.

Cardiff Oncology, Inc. has a diverse shareholder base, including individual investors, institutions, and hedge funds. Institutional investors hold a substantial portion of the stock, with top shareholders including BlackRock, Inc. and Vanguard Group Inc. Individual investors hold a significant stake, and insiders own about 26.32% of the company, with Robert Merrill Hunter being the largest individual shareholder.